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There is no consensus on the management of locally advanced pancreatic cancer, with either chemotherapy or combined modality
approaches being employed (Maheshwari and Moser, 2005). No published meta-analysis (Fung et al, 2003; Banu et al, 2005; Liang,
2005; Bria et al, 2006; Milella et al, 2006) has included randomised controlled trials employing radiation therapy. The aim of this
systematic review was to compare the following: (i) chemoradiation followed by chemotherapy (combined modality therapy) vs best
supportive care (ii) radiotherapy vs chemoradiation (iii) radiotherapy vs combined modality therapy (iv) chemotherapy vs combined
modality therapy (v) 5FU-based combined modality treatment vs another-agent-based combined modality therapy. Relevant
randomised controlled trials were identified by searching databases, trial registers and conference proceedings. The primary end point
was overall survival and secondary end points were progression-free survival/time-to-progression, response rate and adverse events.
Survival data were summarised using hazard ratio (HR) and response-rate/adverse-event data with relative risk. Eleven trials involving
794 patients met the inclusion criteria. Length of survival with chemoradiation was increased compared with radiotherapy alone (two
trials, 168 patients, HR 0.69; 95% confidence interval (CI) 0.51–0.94), but chemoradiation followed by chemotherapy did not lead
to a survival advantage over chemotherapy alone (two trials, 134 patients, HR 0.79; CI 0.32–1.95). Meta-analyses could not be
performed for the other comparisons. A survival benefit was demonstrated for chemoradiation over radiotherapy alone.
Chemoradiation followed by chemotherapy did not demonstrate any survival advantage over chemotherapy alone, but important
clinical differences cannot be ruled out due to the wide CI.
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Pancreatic cancer is a difficult condition to treat, evidenced by the
fact that the annual mortality figures are close to the incidence rate
(Jemal et al, 2006). Ninety per cent of patients have unresectable
disease at diagnosis, of whom 40–50% have locally advanced
disease (White et al, 1999), and reported to have better median
survival of 6–10 months compared to the 3–6 months noted in
metastatic disease (American Cancer Society, 2003). Radiotherapy
approaches, with or without chemotherapy, have been frequently
used in this subset (Maheshwari and Moser, 2005).
Previous meta-analyses in this area have looked at chemother-
apy and novel agents (Fung et al, 2003; Banu et al, 2005; Liang,
2005; Bria et al, 2006; Milella et al, 2006), and the Cochrane
Collaboration (Yip et al, 2006) have done a recent systematic
review on advanced pancreatic cancer that included a qualitative
overview of trials involving radiotherapy, but there has been no
meta-analyses performed to date addressing this treatment option.
Evaluating this approach is important, as currently there is no
uniformly agreed standard of care in the management of patients
with locally advanced disease.
We have attempted an up-to-date analysis of the different
radiotherapeutic options employed in locally advanced pancreatic
cancer, thereby including an area not covered by previous meta-
analyses. Furthermore, we have adopted the most appropriate
statistical methods for meta-analysis of time to event data
extracted from published reports (Parmar et al, 1998).
METHODS
Aims
To review systematically the published and unpublished literature,
comparing the following therapies:
1. Chemoradiotherapy, followed by chemotherapy vs best sup-
portive care
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s2. Radiotherapy vs chemoradiotherapy
3. Radiotherapy vs chemoradiotherapy, followed by chemotherapy
4. Chemotherapy vs chemoradiotherapy, followed by chemo-
therapy (combined modality therapy)
5. 5FU-based chemoradiotherapy followed by chemotherapy vs
another agent-based chemoradiotherapy, followed by chemo-
therapy
Search strategy
Trials were identified by searching MEDLINE, OLDMEDLINE
(1950–1965), EMBASE (1974 to date), ISI Web of Science
(incorporating Science Citation Index 1945 to date; ISI Science
and Technology Proceedings 1990 to date; CancerLit (1960 to date)
and Current contents databases (from 1996 to date) as far back as
they go. In addition, trial registries (Registries of the National
Cancer Institute Physician Data Query, the UK Co-ordinating
Committee on Cancer Research, National Clinical Trials Registry,
and the Cochrane Controlled Trials Register) and conference
proceedings (American Society of Clinical Oncology, American
Association of Cancer Research and the European Cancer
Conference, European Society of Medical Oncology, American
Gastroenterological Association, European Pancreatic Club,
American Association of Pancreatology, British Society of Gastro-
enterology, and the United European Gastroenterology Week)
were searched. References of selected papers and previous
systematic reviews were scanned for any other relevant trials,
and original trialists were contacted for possible unpublished
trials.
Selection criteria
Randomised controlled trials were selected based on their abstract,
or if that was unclear, the paper. Inclusion criteria were
randomised controlled trials involving patients with advanced
pancreatic cancer of the exocrine pancreas, comparing the
therapies listed above. The exclusion criteria were trials which
were nonrandomised, or included surgical resection of tumours
and cancers other than pancreas cancers, wherein data was not
available for the pancreas cancer subset. The study selection was
done by two independent assessors, with any difference of opinion
sorted by discussion.
End points
Overall survival (OS) defined as time from randomisation to death,
was the primary outcome measure. Alternative definitions such as
time from initiation of therapy to death were also included and
noted as a potential source of heterogeneity.
Progression free survival (PFS) or time to progression (TTP),
overall response rate (ORR) and adverse events (AE) were the
secondary outcome measures. PFS was defined as time from
randomisation to progression or death. Time to progression (TTP)
was defined as the time from randomisation to disease progres-
sion. PFS was analysed separately from TTP as the former accounts
for all deaths as well as progression events, whereas the latter only
accounts for progression events. Overall response rate (ORR) was
defined as the number of partial and complete responses and
adverse events defined as side effects occurring from the date of
randomisation till either end of study or death.
Quality assessment
Methodological quality was assessed based on the method of
allocation generation (method of randomisation), allocation
concealment (where the randomisation was carried out), blinding
and losses to follow up. These were classified as adequate,
inadequate or unknown, and the results of the different
components discussed qualitatively.
Data extraction
Data extraction was performed independently by two reviewers
using a standardised data extraction sheet. Disagreements were
resolved by discussion and any data uncertainties forwarded to the
original trialist for clarification.
Statistical analysis
Individual trial level time to event data (OS and PFS/TTP) were
summarised by the log hazard ratio (HR) and its variance. As
many trials do not report this information directly (Altman et al,
1995), appropriate data such as log rank test results were extracted
to allow estimation of the log HR and its variance using previously
reported methods (Parmar et al, 1998; Williamson et al, 2002). One
of these approaches relies on extracting data from published
survival curves (Parmar et al, 1998). The software we used (version
3.0; 28 September, 2004) to estimate the trial level log HR and
variance-based on summary data extracted from published
survival curves was developed by Matthew Sydes and Jayne
Teirney of the MRC Clinical Trials Unit, London. Trial-level log
HRs and their variances were entered into RevMan version 4.2
(a Windows-based software package used by the Cochrane
Collaboration for writing systematic reviews and undertaking
meta-analysis Sterne et al, 2001) and pooled using an inverse
variance weighted average with results presented as a HR and 95%
confidence interval (CI).
Dichotomous data (response rate/adverse events) were sum-
marised using relative risks and 95% CIs with the Mantel–Haensel
method used for pooling results across trials (Deeks et al, 2001).
Heterogeneity was assessed by visual inspection of the forrest
plot, the Cochran’s w
2 test (using a 10% significance level) and
interpretation of the I
2 statistic (percentage of variation due to
heterogeneity with higher values indicating a greater degree of
heterogeneity) (Deeks et al, 2004). The factors set out a priori to
investigate heterogeneity were age, gender, performance status,
previous treatment, site of the cancer (head, body or tail), and the
chemotherapy/radiation used with the dose, combinations, and
frequency. A fixed effect (FE) approach was adopted unless there
was evidence of significant heterogeneity that could not be
adequately explained, in which case a random effects (RE)
approach was used.
Publication bias was assessed by visual inspection of funnel
plots (Light and Pillemer, 1984).
RESULTS
Eleven trials involving 794 patients met the reviews’ inclusion
criteria and six of these trials involving 451 patients were included
in the meta-analyses. The quality of included studies is described
in Table 1.
As there was only one study identified in two comparisons viz.,
chemoradiation, followed by chemotherapy vs best supportive care
(BSC) comparison (Table 2) (Shinchi et al, 2002), and radiotherapy
vs chemoradiation, followed by chemotherapy comparison
(Table 3) (Moertel et al, 1981), a meta-analysis could not be
undertaken for these comparisons.
In the single randomised controlled trial examined (Shinchi
et al, 2002), there was survival advantage for chemoradiation
followed by chemotherapy, over BSC (1 trial, 31 patients, HR 0.28;
95% CI 0.13–0.60). The median time-to-progression was 6.1
months, with overall response rate of 31% (5 out of 16) in the
treated group but corresponding data were not provided for the
BSC group. A quarter of treated patients (4 out of 16) developed
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scomplications secondary to the chemoradiation, with nausea
occurring in three patients and one experiencing grade 2
leucopenia.
There was survival advantage with chemoradiotherapy followed
by chemotherapy over radiation alone (1 trial, 56 patients, HR 0.50;
95% CI 0.29–0.84) in the trial conducted by Moertel et al (1981).
Time to progression was also better in the chemoradiotherapy
followed by chemotherapy arm over radiotherapy alone arm (HR
0.51; 95% CI 0.32–0.81).
Three trials (256 patients) met the inclusion criteria for the
comparison of 5FU-based multimodality therapy vs another-agent-
based multimodality therapy (Table 4). However, meta-analyses
were not performed, as the studies were too clinically hetero-
geneous to be grouped together in a clinically meaningful analysis.
The agents used for radio sensitisation in the non-5FU arm were
different in all three trials, with gemcitabine alone (Li et al, 2003),
gemcitabineþcisplatin (Wilkowski et al, 2006) and adriamycin
(Gastrointestinal Tumour Study Group, 1985) being used.
Adriamycin-based multimodality therapy, using split course
radiotherapy given via two portals, did not demonstrate a
significant survival advantage over 5FU-based treatment (HR for
5FU vs Adriamycin¼0.97 95% CI 0.73–1.29), accompanied by the
drawback of significantly increased adverse events (Po0.05)
(Gastrointestinal Tumour Study Group, 1985).
A randomised controlled trial of 34 patients found significantly
improved overall survival (14.5 vs 6.7 months), time to pro-
gression (7.1 vs 2.7 months) and response rate (50 vs 13%) in
patients treated with gemcitabine-based chemoradiation
(600mgm
 2week
 1 for 6 weeks), followed by gemcitabine, in
comparison to a control arm of 5FU-based chemoradiation
(500mgm
 2day
 1 for 3 days repeated every 2 weeks for 6 weeks),
followed by gemcitabine (Li et al, 2003). Toxicity between the
two arms was similar and radiation had been given using three-
dimensional conformal radiotherapy. These results were not borne
out in a recent randomised controlled trial of 65 patients
(preliminary results), which did not find improvement in 9 month
survival for a group treated with gemcitabine and cisplatin
chemoradiation, vs another treated with protracted venous 5-FU
infusion chemoradiation (Wilkowski et al, 2006).
Comparison of radiotherapy vs chemoradiotherapy
Two randomised controlled trials with 168 patients were included
in this analysis (Table 5) (Moertel et al, 1969; Cohen et al, 2005).
Table 1 Quality of included studies
Comparison Trial
Allocation sequence
generation
Allocation
concealement Blinding Follow-up
Chemoradiotherapy followed by
chemotherapy vs BSC
Shinchi et al (2002) Unclear Unclear Not performed Adequate
Radiotherapy vs chemoradiotherapy, followed
by chemotherapy
Moertel et al (1981) Adequate Adequate Not performed Adequate
5FU-based chemoradiotherapy followed by
chemotherapy vs other agent-based
chemoradiotherapy, followed by
chemotherapy
GITSG (1985) Unclear Adequate Not performed Adequate
Li et al (2003) Unclear Unclear Not performed Adequate
Wilkowski et al (2006) Unclear Unclear Not performed Unclear
Radiotherapy vs chemoradiotherapy Cohen et al (2005) Adequate Adequate Not performed Adequate
Moertel et al (1969) Unclear Unclear Adequate Adequate
Chemotherapy vs chemoradiotherapy,
followed by chemotherapy
GITSG (1988) Adequate Adequate Not performed Adequate
Klassen et al (1985) Adequate Unclear Not performed Adequate
Hazel et al (1981) Unclear Unclear Not performed Adequate
Chauffert et al (2006) Unclear Unclear Not performed Unclear
BSC¼best supportive care; FU¼fluorouracil.
Table 2 Study included in comparison of chemoradiation, followed by chemotherapy vs BSC
Trial Group Mean age and gender Chemotherapy/radio-therapy used and dose
Shinchi et al (2002) Chemoradiation, followed by
chemotherapy (n¼16)
62.9 years; 36% women, 64% men 50.4Gy per 28 fractions and continuous-infusion
5FU 200mgm
 2day
 1
BSC (n¼15) 64.6 years; 67% women, 33% men —
Table 3 Study included in comparison of chemoradiation, followed by chemotherapy vs radiation
Trial Group Mean age and gender Chemotherapy/radio-therapy used and dose
Moertel et al (1981) Chemoradiation, followed by
chemotherapy (n¼31)
62.9 years; 36% women, 64%
men
6000rad, given as 2000rad over 2 weeks and separated
by a 2 weeks’ rest period. A total of 5FU –
500mgm
 2day
 1 on days 1–3 of each 2000rad
radiotherapy course
Radiation alone (n¼25) 64.6 years; 67% women, 33%
men
6000rad
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one described adequate methods of concealment, and both
described adequate losses to follow-up. One trial was blinded
(Table 1).
The HR summarises survival for chemoradiotherapy compared
to radiotherapy with HRo1 indicating a survival advantage for
chemoradiotherapy. Overall survival (Figure 1) was significantly
better, with a 31% reduction in risk of death following
chemoradiotherapy, compared to radiation alone (two trials 168
patients HR 0.69; CI 0.51–0.94 (FE)).
AE data could only be assessed for two parameters, vomiting
and haematological toxicity, and the latter was lower in the
radiotherapy arm compared to the chemoradiation arm (Figure 2).
Cohen et al (2005) did not find any difference in disease-free
survival (HR 0.77; 95% CI 0.52–1.14) or response rate between the
two treatments (RR 1.48; 95% CI 0.37–5.89).
Comparison of chemotherapy to chemoradiotherapy,
followed by chemotherapy
Four randomised controlled trials (Table 6) with 283 patients were
included (Hazel et al, 1981; Klassen et al, 1985; Gastrointestinal
Tumour Study Group, 1988; Chauffert et al, 2006), but overall
survival data for time-to-event analysis was only available in two
studies (134 patients) (Hazel et al, 1981; Klassen et al, 1985).
Adequate methods of allocation generation were described in two
studies, adequate methods of concealment in one study and
adequate losses to follow-up in 3. No study was blinded (Table 1).
The HR summarises survival for chemoradiotherapy, followed
by chemotherapy compared to chemotherapy with HRo1
indicating a survival advantage for chemoradiotherapy, followed
by chemotherapy. Overall survival (Figure 3) was not significantly
better in the chemoradiation, followed by chemotherapy arm
compared to the chemotherapy only arm (two trials 134 patients
HR 0.79; 95% CI 0.32–1.95 (RE)) but the wide CI includes
clinically significant differences in both directions). There was
significant heterogeneity between the two trials analysed (P¼0.01;
I
2¼83.4%).
The Klassen study found no significant difference in time to
progression between the two arms (HR 1.03; 95% CI 0.73–1.47).
No other end points could be analysed for this comparison, owing
to inadequate published data.
Publication bias Despite our exhaustive searches, examination of
the funnel plots revealed evidence of bias, possibly publication
bias, for all comparisons assessed. However, due to the small
number of trials included within most comparisons, interpretation
of funnel plots is difficult.
DISCUSSION
This systematic review includes 11 studies that randomised 794
patients with locally advanced pancreas cancer and represents the
only meta-analyses to date that examine the use of radio-
therapeutic approaches in locally advanced pancreas cancer.
Compared with the Cochrane Collaboration review (Yip et al,
2006), our review excluded two of their studies (Childs et al, 1965;
Earle et al, 1994) but included three additional recent randomised
controlled trials (Cohen et al, 2005; Chauffert et al, 2006;
Wilkowski et al, 2006). The study conducted by Childs et al
(1965) was reported in final form by Moertel et al (1969), and
Table 4 Study included in comparison of 5FU-based chemoradiation, followed by chemotherapy vs another chemotherapy agent-based chemoradiation,
followed by chemotherapy
Authors
Group (number
randomised)
Median age and
gender Chemotherapy/radio-therapy used and dose
Wilkowski et al (2006) 5FU chemoradiotherapy
(n¼32)
NA 5FU 350mgm
 2irradiation day
 1+50Gy conventional radiation
Gemcitabine+cisplatin
chemoradiotherapy (n¼33)
NA Gemcitabine 300mgm
 2day
 1 30min infusion, cisplatin
30mgm
 2day
 1 60min infusion on days 1, 8, 22 and 29+50Gy
conventional radiation
Li et al (2003) 5FU chemoradiotherapy
(n¼16)
69 years; 12 men, 4
women
500mgm
 2day
 1 for 3 days, repeated every 2 weeks for 6
weeks+3D conformal radiotherapy 50.4–61.2Gy
Gemcitabine
chemoradiotherapy (n¼18)
68.5 years; 13 men, 5
women
600mgm
 2week
 1 for 6 weeks+3D conformal radiotherapy 50.4–
61.2Gy
GITSG (1985) 5FU chemoradiotherapy
(n¼79)
5FU 500mgm
 2 on first 3 days of each radiotherapy
course+6000rad double split course, followed by weekly
maintenance with 5FU 500mgm
 2 till progression
Adriamycin
chemoradiotherapy (n¼78)
Adriamycin 15mgm
 2 on day 1; thereafter 10mgm
 2week
 1, for a
minimum of five doses+4000rad continuous course, followed by
weekly maintenance with 5FU 500mgm
 2 till progression
FU¼fluorouracil.
Table 5 Studies included in comparison of radiotherapy vs chemoradiotherapy
Trial Group
Median age and
gender Chemotherapy/radiotherapy used and dose
Moertel et al (1969) Radiotherapy (n¼32) NA 3500–4000rad by cobalt 60 teletherapy unit
Chemoradiotherapy (n¼32) NA 3500–4000rad by cobalt 60 teletherapy unit, 5FU 45mgkg
 1 on first
3 days of radiotherapy
Cohen et al (2005) Radiotherapy (n¼49) 62 years; 55 men, 45
women
Radiotherapy 59.4Gy
Chemoradiotherapy (n¼55) 64 years; 67 men, 33
women
Radiotherapy 59.4Gy, 5FU 1000mgm
 2day
 1 on days 2–5 and
28–31 of radiotherapy MMC 10mgm
 2 on day 2
MMC¼mitomycin; 5FU¼5-fluorouracil.
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study by Earle et al (1994) did not fit into the comparisons that
were being assessed. The most appropriate statistical methods
for meta-analysis of time to event data extracted from published
reports have been used in our report (Parmar et al, 1998).
We did not find any randomised controlled trials that compared
radiation alone or chemoradiation alone to BSC. The basis for
incorporating radiation therapy in pancreatic cancer was based on
a Mayo clinic randomised controlled trial that randomised patients
to receive radiotherapy or 5FU-based radiotherapy (Moertel et al,
1969) and an uncontrolled study of 23 patients who received
radiotherapy (5040–6680rad), with 13 patients also receiving 5FU
(Haslam et al, 1973). Median survival in the study by Haslam et al
(1973) was 7.5 months.
One small randomised controlled trial (Shinchi et al, 2002) of 31
patients compared chemoradiation, followed by chemotherapy, to
BSC. 5FU (200mgm
 2day
 1) was administered for the duration of
the radiation therapy, followed by 500mgm
 2per week thereafter,
until progressive disease or unacceptable toxicity occurred. The
regimen of daily 5FU concomitant with radiation differs from all
the other randomised controlled trials using chemoradiation
(Moertel et al, 1969; Hazel et al, 1981; Klassen et al, 1985;
Gastrointestinal Tumour Study Group, 1988; Cohen et al, 2005;
Chauffert et al, 2006), wherein weekly 5FU (500–1000mgm
 2
given either weekly or on first and last 3 days of radiotherapy) was
used for radio sensitisation. A nonsignificant reduction in liver
and peritoneal metastases was seen in the treatment arm. This
finding, along with significant improvement in overall survival,
may well be an effect of the chemotherapy rather than the
radiation. The fact that the majority of patients died of local
disease progression (62%) in the treatment arm supports this
possibility.
Overall survival was better with chemoradiation compared to
radiotherapy alone. Although there was no statistical heterogeneity
between these two trials, both the inclusion criteria and radiation
techniques differed. Moertel et al (1969) staged patients using
clinical and surgical techniques, whereas Cohen used extensive
imaging, in the form of CT scan of abdomen, chest X-ray and bone
and brain scan, followed by surgical staging. Thus, selection
criteria were more stringent in the latter study. Radiation
techniques have also improved between the 1960s, when Moertel
published his findings, to the 1980s, when the Cohen study was
open to accrual. The latter study questions the merit of combining
these two modalities, in the light of low response rate, poor
survival and increased toxicity. Moreover, neither radiotherapy
nor chemoradiation address the micro metastases present in
patients labelled as locally advanced cancer (Liu and Traverso,
2004; Shoup et al, 2004).
The 1981 GITSG study was instrumental in popularising
multimodality therapy in the treatment of locally advanced
pancreas cancer, as it showed a doubling of survival duration
over radiation alone (Moertel et al, 1981). This was at the price of
Review: 
Comparison:
Outcome:
Study
or sub-category
Moertel et al (1969) 
Cohen et al (2005)
Total (95% CI)
Test for heterogeneity: χz = 0.38, df = 1 (P = 0.54), Iz = 0%
Test for overall effect: Z = 2.36 (P = 0.02)
–0.4900 (0.2500) 
–0.2910 (0.2010)
39.26 
60.74
0.2 0.5 1
Favours chemoRT Favours RT
25
100.00
0.61 (0.38, 1.00) 
0.75 (0.50, 1.11)
0.69 (0.51, 0.94)
Log (hazard ratio) (s.e.)
Hazard ratio (fixed) 
(95% CI)
Hazard ratio (fixed) 
(95% CI)
Weight
(%)
Treatment of advanced pancreatic cancer (Version 07; june 20, 2006)
08 RT vs chemoRT
01 RT vs chemoRT
Figure 1 Overall survival-radiotherapy vs chemoradiotherapy. The plot demonstrates a 31% reduction in risk of death following chemoradiotherapy,
compared to radiation alone (two trials 168 patients HR 0.69; CI 0.51–0.94 (FE)).
Table 6 Included studies – chemotherapy vs chemoradiotherapy, followed by chemotherapy
Authors
Group (number
randomised)
Median age and
gender Chemotherapy/radiotherapy used and dose
Hazel et al (1981) Chemo (n¼15) NA 5FU 500mgm
 2 weekly, methyl CCNU 100mgm
 2 every 6 weeks
Combin rx (n¼15) NA 5FU 500mgm
 2 weekly, radiotherapy 4600rad in 4.5 weeks. After completion of
chemoradiation, methyl CCNU added
Klassen et al (1985) chemo (n¼44) NA; 31 men, 13
women
5FU 600mgm
 2 weekly
Combin rx (n¼47) NA; 22 men, 25
women
5FU 600mgm
 2 on first days of radiotherapy 4000rad radiotherapy over 4 weeks
After completion of chemoradiation, 5FU 600mgm
 2 weekly
GITSG (1988) Chemo (n¼21) 60 years; 13 men, 8
women
5FU 600mgm
 2 on days 1, 8, 29, 36, streptozocin 1gm
 2 every 8 weeks,
mitomycin 10mgm
 2 on day 1 every 8 weeks
Combin rx (n¼22) 61 years; 14 men, 8
women
Radiotherapy 5400rad over 6 weeks with 5FU 350mgm
 2 on first 3 days and last
3 days of radiotherapy. After completion of chemoradiation, chemo-SMF regimen:
5FU 600mgm
 2, streptozocin 1gm
 2 on days 1, 8, 29, 36 every 8 weeks,
mitomycin 5mgm
 2 at first dose, then 10mgm
 2 every 8 weeks
Chauffert et al (2006) Chemotherapy
(n¼60)
Mean age¼60.1
years
Gemcitabine 1000mgm
 2 7q8 weeks initially, then 3q4 weeks
Combination rx
(n¼59)
Mean age¼62.7
years
60Gy in 6 weeks, with 5FU 300mgm
 224h
 1 on days 1–5 every week and
cisplatin 20mgm
 2day
 1 on days 1–5 at week 1 and 5. After completion of
chemoradiation, gemcitabine 1000mgm
 2 3q4 weeks
C, CCNU¼lomustine; chemo¼chemotherapy; Combin rx¼combination therapy (chemoradiotherapy, followed by chemotherapy); MMC¼mitomycin; NA¼data not
available.
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sgreater toxicity, as myelosuppression was more frequent and
severe, and two cases of gastrointestinal bleeding and one instance
of moderate azotemia were reported in the combined modality
arm.
Meta-analysis of chemotherapy vs chemoradiation, followed by
chemotherapy in the two evaluable trials, found no significant
difference between the two approaches, in the presence of inter-
study heterogeneity. This could be owing to the following factors:
(i) Difference in radiation. The GITSG study (Gastrointestinal
Tumour Study Group, 1988) utilised 54Gy, given via three or
four fields whereas the Klassen study (Klassen et al, 1985)
used 4000rad given by parallel-opposed anterior and posterior
portals.
(ii) The chemotherapy agents also differed, with the GITSG study
using a combination of 5FU, streptozotocin and mitomycin C
(SMF), whereas the Klassen study used single agent 5FU.
The difference in effects between the two studies could be due to
the difference in the radiotherapy used, as the GITSG study
concluded that the SMF regimen did not prove to be superior to
single agent 5FU. The CIs here are very wide, with reduction in risk
of death with chemoradiation followed by chemotherapy being, on
one end of the spectrum, as much as 68%, whereas at the other
end, the increase in risk of death being 95% greater compared to
chemotherapy alone. Another point to be borne in mind was that
the GITSG study had closed prematurely, owing to lack of funding,
with the total number of patients accrued only a third of the
planned sample size. Early stoppage of a trial could lead to an
erroneous estimation of treatment effects, with a propensity for
exaggeration, that is, a random high (Schulz and Grimes, 2005).
For the two studies (Hazel et al, 1981; Chauffert et al, 2006) in
this comparison wherein we were unable to calculate HR from the
published data, the overall results did not support the use of
chemoradiotherapy followed by chemotherapy, over chemo-
therapy alone. In the trials conducted by Hazel et al (1981) of 30
patients, there was no significant difference in median survival
between the two arms (7.3 months in multimodality treatment arm
vs 7.8 months in the chemotherapy arm). A recent randomised
controlled trial, done nearly two decades after the GITSG study,
found significant survival advantage (log rank P¼0.014) with
gemcitabine single agent chemotherapy (median survival 14.3
months) over multimodality therapy in locally advanced disease
(median survival¼8.4 months), necessitating early stoppage of the
trial (Chauffert et al, 2006). All studies found greater haemato-
logical toxicity in the multimodality treatment arm, and the
Chauffert study found a higher incidence of nonhaematological
toxicity as well.
To conclude, survival benefit was demonstrated for the
comparison of chemoradiotherapy over radiation alone, with
evidence from a single randomised controlled trial demonstrating
survival benefit for chemoradiotherapy followed by chemotherapy
over radiation alone and chemoradiotherapy followed by chemo-
therapy over BSC. There is insufficient evidence to support the use
of chemoradiation with follow on chemotherapy over chemother-
apy alone in the absence of a survival advantage, coupled with
greater toxicity. However, the wide CIs make it difficult to rule out
important clinical differences. The results of the Intergroup study
E4201, which aimed to compare gemcitabine alone to gemcitabine
and radiation therapy would have helped settle the issue of
whether there is a role, if at all, for multimodality therapy in locally
advanced pancreatic cancer (Lockhart et al, 2005). Unfortunately,
this trial was closed owing to poor accrual and hence the question
remains unanswered (Cardenes et al, 2006).
There are missing links in the chain of evidence using radiation
therapy in advanced pancreas cancer, in particular, the fact that at
inception, radiation alone was not compared against BSC in a
randomised setting, unlike with chemotherapy approaches. In
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saddition, there are several small inadequately powered randomised
controlled trials testing different hypothesis, with a missing golden
thread in the evolution of these studies. Staging has improved over
time, with significant advances in imaging in the last 5 years
following the advent of multidetector row helical CT with or
without positron emission tomography (Michl et al, 2005).
The frontline approaches to staging today are contrast-enhanced
multi-detector row helical CT, with its high sensitivity for
identifying vascular invasion, and endoscopic ultrasound, which
can pick up tumours as small as 2–3mm. In the event of these
modalities being equivocal, there are additional tools available in
the form of MRI with MR-angiography, MRCP, PET/CT and
staging laparoscopy. Radiotherapy has also evolved, from the two-
dimensional split course radiation encompassing larger treatment
volumes with resultant toxicity, to the newer, more targeted three-
dimensional conformal radiation and the intensity modulated
radiation therapy (IMRT) approaches (Garofalo et al, 2006).
Image-guided radiation therapy (IGRT) takes into account the
interfraction and intrafraction dose variation, as a consequence of
organ motion. Better technology and the use of conformal
treatment have led to higher tolerable radiation doses (Yang
et al, 2005). With improvements in staging and radiation
techniques future studies may re-evaluate the application of
upfront chemoradiation or the use of early systemic therapy for
the treatment of micro metastases followed by consolidation
therapy within adequately powered studies.
To conclude, we advocate the use of chemotherapy in patients
with locally advanced cancer, as currently there is insufficient
evidence to endorse the use of chemoradiation, followed by
chemotherapy, over chemotherapy alone. This recommendation is
also supported by a recent meta-analysis, which demonstrated a
significant survival benefit for chemotherapy over BSC and
gemcitabine-based combinations over single agent gemcitabine
in patients with advanced pancreatic cancer (Sultana et al, 2007). It
is important to bear in mind that no randomised controlled trial
has compared radiotherapy to chemotherapy and the single
randomised controlled trials that compared chemoradiation,
followed by chemotherapy to either BSC or radiation, are small.
With improvements in staging and radiation techniques future
trials may influence these recommendations.
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